(Q37315381)

19 August 2017

1 reference

title

Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. (English)

1 reference

19 August 2017

M Suttorp

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

Bone Marrow Transplantation

19 August 2017

published in

1 reference

19 August 2017

volume

42 Suppl 2

1 reference

19 August 2017

page(s)

S40-6

1 reference

Inhibition of c-fms by imatinib: expanding the spectrum of treatment.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

The story of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Stem cell transplantation for chronic myeloid leukemia in children

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Dynamics of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Imatinib as a potential antiresorptive therapy for bone disease.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Long-term imatinib therapy promotes bone formation in CML patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

[Treatment of chronic myeloid leukemia in children and adolescents--concept of the multicenter pilot study CML-ped.]

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

How I treat chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of off European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.282

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.282

1 reference

19 August 2017

1 reference